However, tumors may eventually enter the escape phase, characterized by the suppression or evasion of immune responses, often by subverting the functions of DCs through immunosuppressive cytokines (e.g., IL‐10, TGF‐β) or metabolic constraints within the tumor microenvironment (TME) [2, 4]. The gene discussed is TGFB1; the disease is neoplasm.